Skip to main navigation Skip to search Skip to main content

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV)

Grants and Contracts Details

StatusActive
Effective start/end date9/29/21 → 7/18/27

Funding

  • CNS Pharmaceuticals Incorporated: $226,329.00